Neobet E 0.1% + 0.5%

Ointment

Pack Size : 1 Ointment x 1 Packet

Generics : Betamethasone 0.1% + Neomycin Sulphate 0.5% E/E prep

Manufacturer : Acme Laboratories Ltd.

Best Price * TK 17.02

* Delivery will be done in Dhaka city only.

Alternative Product

Drops Betacin-N Eye drop 5 ML - 5 ML

Tk 35.00

Drops Betacin-N Eye drop 5 ML Ibn Sina Pharmaceutical Ind. Ltd.

Tk 35.00

More Information About - Neobet E 0.1% + 0.5%

Description

Generic Name

Betamethasone 0.1% + Neomycin Sulphate 0.5% E/E prep

Precaution

Topical corticosteroids should never be given for an undiagnosed red eye as inappropriate use is potentially blinding. Treatment with corticosteroid/antibiotic combinations should not be continued for more than 7 days in the absence of any clinical improvement, since prolonged use may lead to occult extension of infection due to the masking effect of the steroid. Prolonged use may also lead to skin sensitisation and the emergence of resistant organisms. Ophthalmological treatment with corticosteroid preparations should not be repeated or prolonged without regular review to exclude raised intraocular pressure, cataract formation or unsuspected infections. Aminoglycoside antibiotics may cause irreversible, partial or total deafness when given systemically or when applied topically to open wounds or damaged skin. This effect is dose related and is enhanced by renal or hepatic impairment. Although this effect has not been reported following topical ocular use, the possibility should be considered when high dose topical treatment is given to small children or infants. Nasal administration of corticosteroids is not advised if an untreated nasal infection is present or if the patient has pulmonary tuberculosis or following nasal surgery (until healing has occurred). Systemic effects of nasal corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids and may vary in individual patients and between different corticosteroid preparations. Potential systemic effects may include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). Visual disturbance may be reported with systemic and topical corticosteroid use.

Indication

Allergic and inflammatory conditions of the eye & ear, otitis externa, uveitis, marginal keratitis, allergic conjunctivitis, blepharitis, episcleritis

Contra Indication

Viral, fungal, tuberculous or purulent conditions of the eye. Fungal infections of the nose or ear. Use is contra-indicated if glaucoma is present or herpetic keratitis (e.g. dendritic ulcer) is considered a possibility. Use of topical steroids in the latter condition can lead to an extension of the ulcer and marked visual deterioration. Otitis externa should not be treated when the eardrum is perforated because of the risk of ototoxicity. Corticosteroids should not be used in patients with a perforated tympanic membrane. Hypersensitivity to any component of the preparation.

Dose

N/A

Side Effect

Hypersensitivity reactions, usually of the delayed type, may occur leading to irritation, burning, stinging, itching and dermatitis. Topical corticosteroid use may result in corneal ulceration, increased intraocular pressure leading to optic nerve damage, reduced visual acuity and visual field defects. Intensive or prolonged use of topical corticosteroids may lead to formation of posterior subcapsular cataracts. In those diseases causing thinning of the cornea or sclera, corticosteroid therapy may result in thinning of the globe leading to perforation. Mydriasis, ptosis, epithelial punctate keratitis and glaucoma have also been reported following ophthalmic use of corticosteroids. Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas. Following nasal administration, the most common effects are nasal irritation and dryness, although sneezing, headache, lightheadedness, urticaria, nausea, epistaxis, rebound congestion, bronchial asthma, perforation of the nasal septum, ulceration of the nasal septum, anosmia, parosmia and disturbance to sense of taste have also been reported. Systemic effects of nasal corticosteroids may occur, particularly at high doses prescribed for prolonged periods. Growth retardation has been reported in children receiving nasal corticosteroids at licensed doses. It is recommended that the height of children receiving prolonged treatment with nasal corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of nasal corticosteroid, if possible, to the lowest dose at which effective control of symptoms is maintained. In addition, consideration should also be given to referring the patient to a paediatric specialist.

Pregnancy Category

Name : Not Classified

Description

FDA has not yet classified the drug into a specified pregnancy category.

Mode of Action

Betamethasone is a corticosteroid which is effective in inflammatory conditions. Neomycin sulfate is a broad spectrum antibiotic. It is bactericidal against many bacteria .

Interaction

If there is significant systemic absorption, neomycin sulfate may increase the respiratory depressant effects of neuromuscular blockers.

Pregnancy Category Note

Safety for use in pregnancy and lactation has not been established. There is inadequate evidence of safety in human pregnancy. Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate and intrauterine growth retardation. There may therefore be a very small risk of such effects in the human foetus. There is a risk of foetal ototoxicity if aminoglycoside antibiotic preparations are administered during pregnancy.

Adult Dose

Eye, Ear & Nasal Drops: Eye: 1 drop instilled into the eye every one or two hours until control is achieved, when the frequency may be reduced. Ear: 2 or 3 drops instilled into the ear, every two or three hours until control is achieved, when the frequency can be reduced. Nose: 2 or 3 drops instilled into each nostril two or three times daily. Eye Ointment: It should be applied thinly and evenly to the conjunctival sac at night (If eye drops used during day) or 3-4 times daily (if ointment used alone).

Child Dose

N/A

Renal Dose

N/A

Administration

Eye Ointment: Apply ? inch long to the lower eye lid 2-3 times daily and/or at night.

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.